The challenges of methotrexate pharmacogenetics in rheumatoid arthritis

Pharmacogenomics

Volumn 13, Issue 4, 2012, Pages 377-

  Ranganathan, Prabha ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ABC TRANSPORTER; METHOTREXATE; REDUCED FOLATE CARRIER;

DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; HUMAN; NOTE; PHARMACOGENETICS; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ARTHRITIS, RHEUMATOID; HUMANS; METHOTREXATE;

EID: 84857776255     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.9     Document Type: Note

References (2)

1. Dervieux T, Wessels JA, Kremer JM et al. Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. Pharmacogenet. Genomics 22(1), 1-9 (2012).
2. Wessels JA, van der Kooij SM, le Cessie S et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56(6), 1765-1775 (2007).